Mbodi, Langanani2020-03-112020-03-112018-11-14Mbodi, Langanani (2018) The outcome of patients with Uterine Carcinosarcoma, University of the Witwatersrand, Johannesburg, <http://hdl.handle.net/10539/29124>https://hdl.handle.net/10539/29124A research report for the fulfillment of the requirement by the MSc (Research) degree of the University of Witwatersrand, 2018Objectives. The study aimed to determine the outcome of women with uterine carcinosarcoma and treated with surgery alone, surgery and adjuvant irradiation or surgery and adjuvant chemotherapy at Charlotte Maxeke Johannesburg Academic hospital (CMJAH). Methods. Women with a histologically confirmed diagnosis of uterine carcinosarcoma managed with the three modalities at CMJAH were selected retrospectively over 10 years. Survival graphs were generated using the Kaplan-Meier method. Results. A total of 32 women met the inclusion criteria for the study. The mean age was 63.34 years (SD±8.65). Total Abdominal Hysterectomy (TAH) & Bilateral Salpingo- Oophorectomy (BSO) was done in 12 (37.50%), TAH/BSO/Washings in 7 (21.88%), TAH /BSO/Omentectomy in 4 (12.50%), TAH/BSO/Washings and Omentectomy in 4 (12.50%) and TAH/BSO/Lymphadenectomy (LND) & Washings in 2 (6.25%) women. There was no statistical association between survival after treatment and uterine size (p=0.638), ECOG status (p=0.571), lymphovascular invasion (p=0.687), treatment with radiotherapy (p=0.202) and recurrence period of disease. The mean survival from surgery was 15.5 months (SD± 88.79) and 11.25 months (SD±66.47) in radiotherapy group. Survival estimates calculations on chemotherapy group were difficult due to small sample. Conclusion. Treatment with radiotherapy or chemotherapy after surgery offers no survival benefit. However, this was a low powered study. The role of nuclear medicine modalities such as Targeted Alpha Therapy (TAT) in carcinosarcoma has not been well explored and perhaps it may offer better outcome.Online resource (50 leaves)enGenitalia, femaleGenital Neoplasms, FemaleThesis